Cyprus Mail 5 February 2020 - article by Gina Agapiou
The decision by the Health Insurance Organisation (HIO) to apply limited access to new-generation drugs for cardiovascular disease was condemned on Wednesday by the Cyprus Patients’ Association.
HIO recently decided to limit access to the new drugs under the health scheme Gesy for cardiovascular diseases without consulting scientists in the field, according to the association.
The association said it “supports all the logical actions concerning Gesy but will also protect patients’ rights from any bad decisions no matter who is taking them, and will fight for the right of the patients to receive the medication they need.”
It also said its representatives met with the HIO and asked them to inform doctors and patients before implementing such decisions.
